Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 7/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31746758 | 1.00 | MAPK8 (0.54) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL25299727 | 0.86 | ADORA2A (0.53) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30578099 | 0.79 | MAPK8 (0.54) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL120846 | 0.79 | MAPK8 (0.54) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13131265 | 0.79 | PTPN2 (0.59) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8110850 | 0.79 | MAPK8 (0.64) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11495421 | 0.79 | RAD51 (0.65) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29138850 | 0.78 | IKBKB (0.36) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11417540 | 0.77 | MAPK8 (0.55) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2947748 | 0.76 | MAPK8 (0.53) | MAPK8HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090311288-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | claimed |
| US-20090232844-A1 | IMMUNOPOTENTIATING COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | claimed |
| EP-2010537-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-01-07 | — | — | EP | claimed |
| EP-2007765-A2 | IMMUNOPOTENTIATING COMPOUNDS | Novartis AG (CH) | 2008-12-31 | — | — | EP | claimed |
| WO-2007109812-A2 | IMMUNOPOTENTIATING COMPOUNDS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | claimed |
| WO-2007109813-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | claimed |
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| EP-3240789-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | Université de Montpellier (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016107895-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2016-07-07 | — | — | WO | disclosed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2357184-B1 | Imidazoquinoxaline compounds as immunomodulators | NOVARTIS AG (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-6124287-A | TREATING DEPRESSION | BIOMEDICA FOSCAMA INDUSTRIA CHIMICOFARMACEUTICA S.P.A. (IT) | 2000-09-26 | — | — | US | disclosed |
| US-6124287-A | TREATING DEPRESSION | BIOMEDICA FOSCAMA INDUSTRIA CHIMICOFARMACEUTICA S.P.A. (IT) | 2000-09-26 | — | — | US | disclosed |
| US-6124287-A | TREATING DEPRESSION | BIOMEDICA FOSCAMA INDUSTRIA CHIMICOFARMACEUTICA S.P.A. (IT) | 2000-09-26 | — | — | US | disclosed |
| EP-0865442-B1 | IMIDAZO[1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOSCAMA BIOMED CHIM FARMA (IT) | 2000-07-05 | — | — | EP | disclosed |
| EP-0865442-B1 | IMIDAZO[1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOSCAMA BIOMED CHIM FARMA (IT) | 2000-07-05 | — | — | EP | disclosed |
| EP-0865442-A1 | IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | Biomedica Foscama Industria Chimico-Farmaceutica S.p.A. (IT) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997019079-A1 | IMIDAZO[1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | MAPK8 1826/4885HTR3E 3553/4885HTR3B 3276/4885 |
| US-20090311288-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | IFNG, MYD88, IRF3 | MAPK8 1029/4885HTR3E 3620/4885HTR3B 3612/4885 |
| US-20090232844-A1 | IMMUNOPOTENTIATING COMPOUNDS | IFNG, LY96, NFATC1 | MAPK8 3254/4885HTR3E 4496/4885HTR3B 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.